Banner
Banner
•••
Horizon 2020 (2014 - 2020)

A Comprehensive ‘Paediatric Preclinical Poc Platform’ to Enable Clinical Molecule Development for Children With Cancer

Last update: May 11, 2020 Last update: 11 May, 2020

Details

Locations: Austria, France, Germany, Italy, Netherlands, Spain, Switzerland, UK
Start Date: Jan 1, 2017
End Date: Dec 31, 2021
Value: € 16 562 831,75
Sectors: Health, Science & Innovation Health, Science & Innovation
Categories: Grants
Date posted: May 11, 2020

Associated funding

Associated experts

Description

Programme: H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic: IMI2-2015-07-05 - A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER

Call for proposal: H2020-JTI-IMI2-2015-07-two-stage

Funding Scheme: IMI2-RIA - Research and Innovation action

Objective: Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive rst-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality- assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs. To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of quali cations needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralizedtesting capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia. With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and e cacious drugs for children with malignant solid tumors

Reference — A Comprehensive ‘Paediatric Preclinical Poc Platform’ to Enable Clinical Molecule Development for Children With Cancer — for Austria, France, Germany, Italy, Netherlands, Spain, Switzerland, UK presented by Horizon 2020 (2014 - 2020) (grants), budget is € 16 562 831,75, in Health, Science & Innovation sectors. Reference — A Comprehensive ‘Paediatric Preclinical Poc Platform’ to Enable Clinical Molecule Development for Children With Cancer — for Austria, France, Germany, Italy, Netherlands, Spain, Switzerland, UK presented by Horizon 2020 (2014 - 2020) (grants), budget is € 16 562 831,75, in Health, Science & Innovation sectors. Re...
Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.